Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;58(4):269-278.
doi: 10.4314/gmj.v58i4.4.

A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy

Brainard A Asare  1 , Grace Asare  2
Affiliations

A health facility-based assessment of the ancillary benefit for prevention of anaemia at term of intermittent preventive therapy with sulfadoxine-pyrimethamine in pregnancy

Brainard A Asare et al. Ghana Med J. 2024 Dec.

Abstract

Objective: This study aims to evaluate the ancillary benefit of intermittent preventive therapy with sulfadoxine-pyrimethamine (IPTp-SP) in preventing maternal anaemia (MA) among parturient women differentially exposed to the regimen.

Design: A health facility-based retrospective analytical cross-sectional study.

Settings: The study was conducted at the Kade Government Hospital's maternity/labor suit.

Participants: Data from 2,545 parturient women were abstracted from birth registers.

Statistical analysis: Baseline characteristics were described, and stratified analyses assessed their impacts. Differences in mean mHgbc based on IPTp-SP exposure were determined using one-way ANOVA. An unpaired two-sample t-test evaluated the significance of inter-dose group differences. The bivariable analysis examined crude and adjusted risks of anaemia with differential IPTp-SP exposure.

Main outcome measure: The main outcome measure was the level of mHgbc with varying IPTp-SP exposure.

Results: The overall mean exposure to IPTp-SP was 2.35 (±2.35) doses. Of the women, 5.9% had 'nil' exposure, with a mean mHgbc of 9.71 g/dL (±1.6). Among the 75.9% who received 1-3 doses, the mean mHgbc was 10.39 g/dL (±1.3). For the 18.2% who received ≥4 doses, the mean mHgbc was 10.77 g/dL (±1.4). The mHgbc notably rose as the mean doses of IPTp-SP increased. The crude odds ratios (COR) were 1.96 (95% CI: 0.99-3.89, p = 0.06) for 'nil' exposure, 1.28 (95% CI: 0.92-1.78, p = 0.16) for 1-3 doses, and 0.59 (95% CI: 0.41-0.84, p = 0.002) for ≥4 doses.

Conclusion: The consistent linear increase in mean mHgbc with higher IPTp-SP doses remains clinically crucial.

Funding: None declared.

Keywords: Intermittent; anaemia; benefit; maternal; pregnancy; preventive; therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

References

    1. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001;357(9267):1471–1477. - PubMed
    1. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in an area of high, seasonal transmission in Ghana. BMJ. 2005;331(7519):727–733. - PMC - PubMed
    1. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis. 2006;194(3):276–285. - PubMed
    1. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, Potschke M, et al. Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial. J Infect Dis. 2007;196(11):1595–1602. - PubMed
    1. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson PA, et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis. 2007;45(1):16–25. - PubMed

MeSH terms